Bibliographic citations
Horna, A., (2022). Potenciales interacciones farmacológicas en pacientes pediátricos con trasplante renal de un Hospital Nacional nivel III, febrero 2019 – febrero 2020 [Universidad Nacional de Trujillo]. https://hdl.handle.net/20.500.14414/19740
Horna, A., Potenciales interacciones farmacológicas en pacientes pediátricos con trasplante renal de un Hospital Nacional nivel III, febrero 2019 – febrero 2020 []. PE: Universidad Nacional de Trujillo; 2022. https://hdl.handle.net/20.500.14414/19740
@misc{renati/1047490,
title = "Potenciales interacciones farmacológicas en pacientes pediátricos con trasplante renal de un Hospital Nacional nivel III, febrero 2019 – febrero 2020",
author = "Horna Rodriguez, Alexsandra Milagritos",
publisher = "Universidad Nacional de Trujillo",
year = "2022"
}
ABSTRACT Kidney transplant patients are prescribed several drugs, including immunosuppressive agents, which have a narrow therapeutic margin, which can probably be an important cause of potential drug interactions (PDI). The objective of this research was to analyze the characteristics of PDI in medical prescriptions for pediatric patients with kidney transplants at a National Level III Hospital. This cross-sectional investigation reviewed the medical prescriptions of twelve pediatric kidney transplant patients who were hospitalized in the Pediatric Clinical Specialties unit for no less than 7 days between February 2019 and February 2020. The patients were characterized according to gender. , age group, number of medications prescribed on days 1, 4 and 7 of hospital stay and type of donor. Interactions were identified using the Drug Interaction Checker – Medscape Reference and Drug Interaction Checker – Drugs.com databases, and the R v. computer language was used for statistical analysis. 4.2.0 and the IMB SPSS Statistics v. 25.0. The results showed a higher percentage of male patients 66,7%; aged between 6 to 11 years (58,3%); the number of drugs most prescribed was from 6 to 9 for the three days and the type of donor with the highest percentage was cadaveric 66,7%. The prevalence of PDI was 100,0%; likewise, those of male sex, aged between 6 to 11 years, with 6 to 9 prescribed medications and type of cadaveric donor had a greater presence of PDI. When analyzing the PDI, a total of 342 was found, and a significant relationship was found with the characteristics of age and type of donor (p < 0,05). In the characteristics of PDIs of severe and greater severity, 76,47% were of the synergistic type, classifying as a pharmacodynamic interaction. Interactions of moderate severity 59,7% were classified as type of pharmacokinetic interaction, specifically at the level of absorption (21,18%) and metabolism (29,06%). Likewise, less serious interactions were found within the pharmacokinetic interactions (71,83%). There was no significant relationship (p > 0,05) between the characteristics of the patients and the level of severity of interaction, in all cases; however, the highest percentages of interaction occurred with the moderate severity level. Finally, 59,4% were classified as a moderate severity interaction. Although potential drug interactions have only been evaluated in pediatric kidney transplant patients, knowing the possible mechanism of interaction and the level of severity would help physicians adjust treatment regimens, and joint work with clinical pharmacists would facilitate the interchangeability and individualization of treatment and there would be greater efficacy and safety in pharmacological treatment.
This item is licensed under a Creative Commons License